Therapeutic outcomes of neoadjuvant and concurrent androgen‐deprivation therapy and intensity‐modulated radiation therapy with gold marker implantation for intermediate‐risk and high‐risk prostate cancer
1. Prostate Center and Division of Urology, Chiba Cancer Center, Chiba, Japan;2. Division of Radiation Oncology, Chiba Cancer Center, Chiba, Japan;3. Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan